欧盟集中授权产品用药错误风险管理描述
本研究基于欧洲公共评估报告登记处,收集2010至2017年集中授权原研产品的风险管理计划中用药错误安全性关切,按ATC代码、授权年份、错误类型和风险最小化措施分类。311个产品中84个至少有一项用药错误安全性关切,共识别95项关切,给药错误最常见(n=17);27项关切对应23个产品需额外风险最小化措施,均为针对医护人员和/或患者的教育材料。
要点
- 近四分之一集中授权产品存在用药错误安全性关切
- 给药错误是最常见类型(n=17)
- 额外风险最小化措施均为教育材料
核心结论
- 研究期间近四分之一集中授权产品列有用药错误安全性关切。
- 需进一步研究评估额外风险最小化措施的有效性和持续必要性。
研究设计与样本
- 共311个集中授权产品获批,其中84个至少有一项用药错误安全性关切。
主要发现
- 2010至2017年间,有用药错误安全性关切的集中授权产品比例范围为15.2%至36.4%。
- 共识别95项用药错误安全性关切,给药错误最常见(n=17)。
- 95项关切中27项(对应23个产品)需额外风险最小化措施。
- 所有额外风险最小化措施均为针对医护人员(85.2%)和/或患者(51.9%)的教育材料。
- 78.3%有用药错误额外风险最小化措施的产品同意了评估措施有效性的研究。
临床怎么用
- 临床药师应关注集中授权产品风险管理计划中的用药错误安全性关切,尤其给药错误。
- 对于需额外风险最小化措施的产品,应配合实施针对医护人员和患者的教育材料。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Medication errors can have serious consequences for patients. To prevent the occurrence of medication errors in clinical practice, safety concerns may be included in the risk management plan and subsequently be addressed with routine and/or additional risk minimisation measures. OBJECTIVE: This study aims to describe safety concerns around medication errors and the risk minimisation measures for centrally authorised products in the European Union. METHODS: All safety concerns included in the risk management plans of originator centrally authorised products, authorised between 1 January, 2010 and 31 December, 2017, were collected from the European Public Assessment Report registry. Medication error safety concerns were categorised by Anatomical Therapeutic Classification code, year of authorisation, type of medication error and type of risk minimisation measure. RESULTS: During the study period, 311 centrally authorised products were approved, of which 84 had at least one medication error safety concern. The proportion of centrally authorised products with medication error safety concerns showed variation between 2010 and 2017 ranging from 15.2% to 36.4%. In total, 95 medication error safety concerns were identified. The type of medication error was highly variable, drug administration error was listed most frequently (n = 17). For 27 out of 95 medication error safety concerns, corresponding to 23 centrally authorised products, additional risk minimisation measures were required. All additional risk minimisation measures consisted of educational material targeted at healthcare professionals (85.2%) and/or patients (51.9%). For 78.3% of centrally authorised products with additional risk minimisation measures for medication errors, studies to evaluate the effectiveness of the additional risk minimisation measures were agreed upon. CONCLUSIONS: Medication error safety concerns were listed for almost a quarter of centrally authorised products approved during the study period. Further research is needed to evaluate the effectiveness and continued need for additional risk minimisation measures for medication errors.
引用
- Hoeve CE, Francisca RDC, Zomerdijk I, et al. Description of the Risk Management of Medication Errors for Centrally Authorised Products in the European Union. Drug Saf. 2020. PMID: 31617081. doi:10.1007/s40264-019-00874-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。